Table 1 Baseline patient demographics and disease characteristics
2 % tofacitinib BID | 1 % tofacitinib BID | Vehicle BID | 2 % tofacitinib QD | 1 % tofacitinib QD | Vehicle QD | |
|---|---|---|---|---|---|---|
N = 71 | N = 70 | N = 71 | N = 70 | N = 74 | N = 74 | |
Age (years) | ||||||
Mean (SD) | 47.6 (15.6) | 50.4 (14.5) | 48.8 (15.0) | 50.7 (13.2) | 47.8 (14.0) | 48.9 (13.9) |
Range | 18.0–74.0 | 18.0–77.0 | 21.0–84.0 | 21.0–77.0 | 20.0–85.0 | 20.0–74.0 |
Male (%) | 60.6 | 67.1 | 57.7 | 52.9 | 67.6 | 56.8 |
BMI (kg/m2) | ||||||
Mean (SD) | 31.8 (7.9) | 29.6 (5.6) | 30.2 (8.3) | 28.9 (7.8) | 31.0 (7.2) | 31.1 (6.5) |
Range | 17.2–58.4 | 19.2–51.4 | 17.0–79.8 | 16.4–68.6 | 17.6–50.4 | 20.6–47.4 |
Race (%) | ||||||
White | 93.0 | 85.7 | 94.4 | 90.0 | 91.9 | 97.3 |
Black | 1.4 | 4.3 | 1.4 | 1.4 | 2.7 | 2.7 |
Asian | 4.2 | 7.1 | 2.8 | 5.7 | 2.7 | 0.0 |
Other | 1.4 | 2.9 | 1.4 | 2.9 | 2.7 | 0.0 |
Geographical region (%) | ||||||
Canada | 15.5 | 30.0 | 26.8 | 27.1 | 23.0 | 33.8 |
Denmark | 1.4 | 1.4 | 0.0 | 1.4 | 1.4 | 1.4 |
Poland | 14.1 | 12.9 | 15.5 | 32.9 | 39.2 | 28.4 |
United States | 69.0 | 55.7 | 57.7 | 38.6 | 36.5 | 36.5 |
PGA-C (%) | ||||||
Mild | 28.2 | 30.0 | 29.6 | 32.9 | 27.0 | 27.0 |
Moderate | 71.8 | 70.0 | 70.4 | 67.1 | 73.0 | 73.0 |
PASI score | ||||||
Mean (SD) | 9.5 (5.1) | 8.5 (3.3) | 8.5 (3.6) | 9.9 (4.1) | 10.1 (4.4) | 9.6 (3.8) |
Range | 2.4–29.0 | 3.0–18.0 | 2.4–18.0 | 2.0–19.8 | 2.8–19.8 | 3.2–17.1 |
BSA (%) | ||||||
Mean (SD) | 7.6 (4.6) | 6.4 (3.8) | 6.5 (4.1) | 7.8 (4.3) | 8.4 (4.9) | 8.0 (4.5) |
Range | 2.0–19.0 | 1.5–17.0 | 2.0–20.0 | 2.0–19.0 | 2.4–20.0 | 2.0–19.0 |
ISI scorea | ||||||
Mean (SD) | 5.8 (2.6) | 5.3 (2.4) | 5.4 (2.6) | 6.0 (2.7) | 5.7 (2.9) | 5.4 (3.0) |
Range | 0.0–10.0 | 1.0–10.0 | 0.0–10.0 | 0.0–10.0 | 0.0–10.0 | 0.0–10.0 |
DLQI | ||||||
Mean (SD) | 10.6 (5.9) | 8.6 (5.5) | 9.3 (6.0) | 12.2 (7.4) | 10.9 (7.0) | 10.2 (6.5) |
Range | 0.0–25.0 | 1.0–25.0 | 1.0–24.0 | 1.0–29.0 | 1.0–29.0 | 0.0–26.0 |